Ark Therapeutics Limited

Arktherapeutics Group, Plc

Yale University

Magnus Flow Limited

Finvector Vision Therapies, Ltd.

John Martin

Hugh Edward Montgomery

Jorge Daniel Erusalimsky

Anthony Mathur

Tarek M Fahmy

Stephen George Edward Barker

Seppo Yla-Herttuala

Jung Seok Lee

Dongin Kim

Charles Henry Rodeck

It has been discovered that iron-platinum ferromagnetic particles can be dispersed in a polymer and coated into or onto, or directly linked to or embedded on to, medical devices and magnetized. The magnetized devices are used to attract, capture, and/or retain magnetically labeled cells on the surface of the device in vivo. The magnetic particles have an iron/platinum core. Annealing the Fe/Pt particle is very important for introducing a L10 interior crystalline phase. The Fe:Pt molar ratio for creation of the crystal phase is important and a molar range of 1.2-3.0 Fe to Pt (molar precursors, i.e. starting compounds) is desired for magnetization. The magnetic force as a whole can be measured with a 'Super Conducting Quantum Interference Device', which is a sensitive magnetometer. The overall magnetic force is in the range from 0.1 to 2.0 Tesla.

Iron platinum particles for adherence of biologics on medical implants

A biosorbable magnetisable endoprosthesis, may be useful in the therapy of restenosis. A method for the treatment of prevention of restenosis or a disease of the coronary artery, comprises fitting a patent with an endoprosthesis according to the invention, which has either been magnetized prior to placement in the body or which is magnetized in situ, and administering to the patient magnetized cells capable of repairing an artery.

Biosorbable endoprosthesis

It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

Use of inhibitors of the renin-angiotensin system

An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF agonist may be a VEGF peptide or a gene construct encoding or expressing such a peptide.

Use of VEGF in the treatment of retarded fetal growth in pregnancy

Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.

The present invention concerns vascular endothelial growth factor (VEGF) which has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g., using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered.

Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia

It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.

Growing community of inventors

London, United Kingdom

John Martin